Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

导出 OA

翻译打印收藏纠错

作者： Joan L,Walker ^[1] ; Mark F,Brady ^[2] ; Lari,Wenzel ^[3] ; Gini F,Fleming ^[4] ; Helen Q,Huang ^[2] ; Paul A,DiSilvestro ^[5] ; Keiichi,Fujiwara ^[6] ; David S,Alberts ^[7] ; Wenxin,Zheng ^[8] ; Krishnansu S,Tewari ^[3] ; David E,Cohn ^[9] ; Matthew A,Powell ^[10] ; Linda,Van Le ^[11] ; Susan A,Davidson ^[12] ; Heidi J,Gray ^[13] ; Peter G,Rose ^[14] ; Carol,Aghajanian ^[15] ; Tashanna,Myers ^[16] ; Angeles,Alvarez Secord ^[17] ; Stephen C,Rubin ^[18] ; Robert S,Mannel ^[1]

作者单位： 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK. ^[1] 2 Roswell Park Cancer Institute, Buffalo, NY. ^[2] 3 University of California, Irvine, Medical Center, Orange, CA. ^[3] 4 The University of Chicago Medicine, Chicago, IL. ^[4] 5 Women and Infants Hospital, Providence, RI. ^[5] 6 Saitama Medical University International Medical Center, Hidaka-Shi, Japan. ^[6] 7 The University of Arizona Cancer Center, Tucson, AZ. ^[7] 8 The University of Arizona, Tucson, AZ. ^[8] 9 The Ohio State University, Columbus, OH. ^[9] 10 Washington University in St Louis, St Louis, MO. ^[10] 11 University of North Carolina at Chapel Hill, Chapel Hill, NC. ^[11] 12 University of Colorado, Aurora, CO. ^[12] 13 University of Washington School of Medicine, Seattle, WA. ^[13] 14 Cleveland Clinic Foundation, Cleveland, OH. ^[14] 15 Memorial Sloan Kettering Cancer Center, New York, NY. ^[15] 16 University of Connecticut, Storrs, CT. ^[16] 17 Duke University Health System, Durham, NC. ^[17] 18 University of Pennsylvania, Philadelphia, PA. ^[18]